Team

COVID-19 rapid response team

  • Vuong Trieu PhD, CEO
    • Co-inventor and scientific lead for Abraxane- reformulated paclitaxel with > 1B in annual sales
    • Cynviloq- repositioned as next generation Abraxane. Sold to NantPharm for 1.3B
    • Founder of Oncotelic which recently acquired Mateon and has successfully repositioned pipeline
    • Trained under French Anderson with significant experience in infectious diseases

 

  • Dr. Seymour Fein MD
    • 35-years in drug development
    • Involved in FDA approvals for over 20 drugs and devices
    • Led clinical program at Hoffmann-La Roche for FDA approval of recombinant interferon-alpha for cancer treatment
    • Formerly Medical Director at Bayer for therapeutic areas including oncology, and cardiology
    • Led FDA approval of two orphan drug products in the field of gastroenterology
    • through Phase 3 development, while growing revenues to over $55 million

 

  • Cyril Empig PhD
    • 15+ years experience in infectious diseases including vaccines and therapeutics
    • Led a $44 million Defense Threat Reduction Agency (DTRA) project for the treatment of hemorrhagic fever viruses using human monoclonal antibodies.
    • Experienced throughout all stages of pharmaceutical product development from discovery through phase 3 at Nantbio, Peregrine, Pain Therapeutics, and Vaxgen.

 

  • Saran Saund, Chief Business Officer
    • Founder of PointR Data, an AI company which is now part of Mateon- Saran is a seasoned technologist, business executive and investor with proven track record for over 25 years in Silicon Valley by founding several successful startups and holding senior executive roles at many public and private companies

 

  • Steven King
    • Former CEO of Peregrine Pharmaceuticals, Inc. (NASDAQ) and its wholly-owned contract biomanufacturing subsidiary Avid Bioservices, Inc., for over 15 years, during which time the company advanced its lead compound through Phase 3 development, while growing revenues to over $55 million